Fineline Cube

Follow:
14486 Articles
VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies
CompanyDeals

VivaVision Biotech Closes D2+ Funding Round, Advancing Ophthalmic Therapies

Youcare Pharma Subsidiary Gains NMPA Clearance for Phase I Study of siRNA Hypertension Drug YKYY029
CompanyDrug

Youcare Pharma Subsidiary Gains NMPA Clearance for Phase I Study of siRNA Hypertension Drug YKYY029

GSK's Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma
CompanyDrug

GSK’s Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma

Robo Medical Secures Tens of Millions in Funding for EndoFaster and EndoDreams Development
CompanyDeals

Robo Medical Secures Tens of Millions in Funding for EndoFaster and EndoDreams Development

CanSinoBio Receives NMPA Approval for Phase I/II Trial of Recombinant Polio Vaccine
CompanyDrug

CanSino Bio Receives NMPA Approval for Phase I/II Trial of Recombinant Polio Vaccine

Yifan Pharma's Generic Glycerol Phenylbutyrate Accepted for NMPA Review
CompanyDrug

Yifan Pharma’s Generic Glycerol Phenylbutyrate Accepted for NMPA Review

Hengrui Pharmaceuticals' SHR-8068 Gains NMPA Approval for NSCLC and Colorectal Cancer Trials
CompanyDrug

Hengrui Pharmaceuticals’ SHR-8068 Gains NMPA Approval for NSCLC and Colorectal Cancer Trials

Fosun Pharma's Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004
CompanyDrug

Fosun Pharma’s Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004

Legend Biotech's Carvykti Achieves USD 439 Million in Q2 2025 Sales
CompanyDrug

Legend Biotech’s Carvykti Achieves USD 439 Million in Q2 2025 Sales

Buchang Pharma Subsidiary Establishes Shaanxi Buchang MedData with Lingyishushu
CompanyDeals

Buchang Pharma Subsidiary Establishes Shaanxi Buchang MedData with Lingyishushu

Novartis Reports Double-Digit Growth in Q2 and 1H25, Driven by Key Brands
Company

Novartis Reports Double-Digit Growth in Q2 and 1H25, Driven by Key Brands

Takeda's Oveporexton Meets All Endpoints in Phase 3 Narcolepsy Type 1 Trials
CompanyDrug

Takeda’s Oveporexton Meets All Endpoints in Phase 3 Narcolepsy Type 1 Trials